Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
613 A phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)
Compose a Response to This Article
Other responses
No responses have been published for this article.
